Paediatric drug optimization for neglected tropical diseases PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Paediatric drug optimization for neglected tropical diseases PDF full book. Access full book title Paediatric drug optimization for neglected tropical diseases by World Health Organization. Download full books in PDF and EPUB format.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240085173
Category : Business & Economics
Languages : en
Pages : 56
Get Book Here
Book Description
Priority-setting is the first step to enable a targeted approach to research and development. Developing a prioritized drug portfolio of the most needed formulations for children is essential to streamline researchers’ and supplier’s efforts and resources around specific dosage forms and formulations that address most urgent needs for children. In general, due to limited financial incentives, few new drugs are being developed for Neglected Tropical Diseases (NTDs). Several NTDs disproportionately affect children compared to adults and, as is the case like for most diseases affecting adults and children, the burden to children is compounded by lack of inclusion of paediatric populations in clinical trials and/or lack of age-appropriate dosing regimens and formulations. The PADO-NTD exercise concluded with a final meeting organized in September 2023 with representatives from the four prioritized disease areas to reach consensus on a final PADO-NTD priority list, watch list and research questions and discuss transversal issues for the way forward. The meeting report will include summaries of the background, discussions and deliberations of all PADO exercises, and final conclusions and outputs of the overall PADO for NTD exercises.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240085173
Category : Business & Economics
Languages : en
Pages : 56
Get Book Here
Book Description
Priority-setting is the first step to enable a targeted approach to research and development. Developing a prioritized drug portfolio of the most needed formulations for children is essential to streamline researchers’ and supplier’s efforts and resources around specific dosage forms and formulations that address most urgent needs for children. In general, due to limited financial incentives, few new drugs are being developed for Neglected Tropical Diseases (NTDs). Several NTDs disproportionately affect children compared to adults and, as is the case like for most diseases affecting adults and children, the burden to children is compounded by lack of inclusion of paediatric populations in clinical trials and/or lack of age-appropriate dosing regimens and formulations. The PADO-NTD exercise concluded with a final meeting organized in September 2023 with representatives from the four prioritized disease areas to reach consensus on a final PADO-NTD priority list, watch list and research questions and discuss transversal issues for the way forward. The meeting report will include summaries of the background, discussions and deliberations of all PADO exercises, and final conclusions and outputs of the overall PADO for NTD exercises.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240101055
Category : Medical
Languages : en
Pages : 33
Get Book Here
Book Description
The goal of the Paediatric drug optimization for cancer exercise was to develop a PADO priority list of formulations to be prioritized with a time horizon of 3–5 years, and a PADO ‘watch list’ containing promising candidates for investigation and development for children with a time horizon of 5–10 years. The PADO–cancer exercise enables alignment between funders, procurers, market-coordination entities, researchers, innovators, generics manufacturers, product development partnerships and regulators on priority products to be investigated and developed, as well as increasing efforts to tackle challenges in access to cancer medicines in LMICs.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240101136
Category : Medical
Languages : en
Pages : 13
Get Book Here
Book Description
Neglected tropical diseases (NTDs) are a diverse set of 21 diseases and disease groups that mainly affect resource-poor populations in tropical and subtropical countries. In general, due to limited financial incentives, few new drugs are being developed for NTDs. This Technical Brief provides succinct information on the current R&D situation in terms of treatments for NTDs in children and existing gaps, with a view to addressing these gaps and supporting the research agenda setting.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240056904
Category : Medical
Languages : en
Pages : 56
Get Book Here
Book Description
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240062041
Category : Medical
Languages : en
Pages : 17
Get Book Here
Book Description
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240083030
Category : Medical
Languages : en
Pages : 16
Get Book Here
Book Description
The STAG Working Group on access to safe, efficacious and quality-assured health products for neglected tropical diseases was established in 2021 to facilitate alignment of stakeholders on strategies and best practices for improving access to medicines and other health products for NTDs. The Working Group held its second technical meeting virtually on 19 September 2023. The main outcomes of the meeting were to expand the scope of drug efficacy monitoring to include other neglected tropical diseases and to seek synergy in addressing common issues and challenges across diseases for procurement and supply chain management. In addition to the Working Group’s members, observers, invited guests and the WHO secretariat attended the meeting. This publication contains the report of the meeting and its recommendations to STAG, which will be helpful as a reference and of use to the wider NTD community.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240091270
Category : Business & Economics
Languages : en
Pages : 31
Get Book Here
Book Description
The Paediatric Regulatory Network was initially created as a global paediatric working group in February 2010 in response to a recommendation from the 2008 International Conference on Drug Regulatory Authorities and as part of the World Health Organization (WHO) Better Medicines for Children Project in collaboration with the Bill & Melinda Gates Foundation, to offer a platform for discussion on paediatric regulatory considerations for national regulatory authorities. The Network was reactivated in December 2019 as a global paediatric network supporting the availability of quality-assured medical products for children, by facilitating communication, collaboration, training and regulatory harmonization across the development, registration and pharmacovigilance of paediatric medical products. The Network’s activities contribute efficiently to the implementation of World Health Assembly resolutions WHA60.20 (2007) on better medicines for children, WHA69.20 (2016) on promoting innovation and access to quality, safe, efficacious and affordable medicines for children, WHA67.20 (2014) on regulatory system strengthening for medical products and WHA67.22 (2014) on access to essential medicines.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240094822
Category : Medical
Languages : en
Pages : 56
Get Book Here
Book Description
Paediatric drug optimization (PADO) exercises have been convened by the World Health Organization (WHO) for various diseases, demonstrating their potential and impact to accelerate access to optimal formulations in the context of fragmented small markets for medicines for children. The WHO Global Tuberculosis Programme has convened PADO-TB meetings since February 2019 (PADO-TB1), followed by an interim review of the PADO-TB1 priorities in September 2020. Optimization of paediatric TB medicines forms part of the key actions in the Roadmap towards ending TB in children and adolescents, third edition and contributes to the achievement of the targets for ending TB in children and adolescents set out at the second United Nations High-level Meeting on the Fight Against TB in 2023. Considering the latest WHO recommendations on drug-susceptible TB, drug-resistant TB and TB preventive treatment, recent developments in new TB medicines and formulations made available, results of clinical trials and studies, and advancements of key medicines in the TB R&D pipeline, WHO convened the second PADO-TB meeting (PADO-TB2) on 3–5 October 2023. This meeting report summarizes the proceedings, discussions and the main consensus-based outputs of the PADO-TB2 meeting: - PADO-TB2 priority list (priority formulations to be investigated/developed in the short term and essential formulations to be developed in the longer term) - PADO-TB2 watch list (promising candidates for investigation/development for children within 5–10 years) - Priority research questions.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240091238
Category : Medical
Languages : en
Pages : 111
Get Book Here
Book Description
Concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypanosomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on Neglected tropical diseases, adopted in 2013. National sleeping sickness control programmes (NSSCPs) are core to progressing in the control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for these achievements. More than 20 years of partnership among WHO, Sanofi and Bayer have enabled WHO to strengthen and sustain financial, technical and material support for the implementation of control activities in countries where HAT is endemic. The long-term support from the Government of Belgium, the Bill & Melinda Gates Foundation (BMGF) and other research institutions in the Democratic Republic of the Congo (DRC) has also been essential. WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandemic and jointly for both forms of the disease. The previous meetings on g-HAT held in 2014, 2016 and 2018, as well as on r-HAT in 2015, 2017 and 2019, and jointly for g-HAT and r-HAT in 2021 (8) reinforced the partnership and commitment for HAT elimination and structured the mechanisms of collaboration within the WHO network for HAT elimination. The network includes NSSCPs, groups developing new tools, international and nongovernmental organizations involved in disease control, and donors. Fewer than 1000 cases of HAT annually have been reported over the past 5 years, which is a historic achievement. The area at risk has been substantially reduced. The elimination of HAT as a public health problem at the global level has been achieved. The new road map for neglected tropical diseases (NTDs) 2021−2030 (“the road map”) with the target to interrupt the transmission of g-HAT requires the strengthened and sustained efforts of all stakeholders, national authorities and partners, under WHO coordination. It will take disproportionally high efforts and innovative strategies to find the last cases of g-HAT and neutralize its transmission. Given the limited resources and other competing public health priorities, this is a challenge that requires our joint commitment.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240102345
Category : Medical
Languages : en
Pages : 25
Get Book Here
Book Description
The GAP-f Phase 2 Progress Report highlights the network’s achievements and milestones from 2022 to 2024, providing a transparent overview of its impact. The report offers open, transparent, and comprehensive accountability to GAP-f’s partners, supporters, and beneficiaries, highlighting the impact of collaborative initiatives. By showcasing progress, pinpointing areas for continued focus, and sharing insights gained, the report serves as a vital tool for sustaining trust and engagement with stakeholders and guiding the planning and focus of GAP-f’s next strategic phase.
